These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 10878819)

  • 81. Familial and sporadic Parkinson's disease usually display the same clinical features.
    Carr J; de la Fuente-Fernández R; Schulzer M; Mak E; Calne SM; Calne DB
    Parkinsonism Relat Disord; 2003 Mar; 9(4):201-4. PubMed ID: 12618054
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Genetic and environmental risk factors in Parkinson's disease.
    Veldman BA; Wijn AM; Knoers N; Praamstra P; Horstink MW
    Clin Neurol Neurosurg; 1998 Mar; 100(1):15-26. PubMed ID: 9637199
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Etiology and physiopathology of patients with parkinson's disease].
    Ogawa N
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1394-9. PubMed ID: 13677885
    [No Abstract]   [Full Text] [Related]  

  • 84. Alpha-synuclein gene triplication discovered in Parkinson's disease.
    Bradbury J
    Lancet Neurol; 2003 Dec; 2(12):715. PubMed ID: 14649238
    [No Abstract]   [Full Text] [Related]  

  • 85. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction.
    Greten-Harrison B; Polydoro M; Morimoto-Tomita M; Diao L; Williams AM; Nie EH; Makani S; Tian N; Castillo PE; Buchman VL; Chandra SS
    Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19573-8. PubMed ID: 20974939
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Spectrum of phenotypes and genotypes in Parkinson's disease.
    Riess O; Krüger R; Schulz JB
    J Neurol; 2002 Oct; 249 Suppl 3():III/15-20. PubMed ID: 12522566
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Parkin gene therapy could treat Parkinson's disease.
    Butcher J
    Lancet Neurol; 2005 Feb; 4(2):82. PubMed ID: 15709224
    [No Abstract]   [Full Text] [Related]  

  • 88. Meta-analysis of alpha synuclein/ NACP polymorphism in Parkinson's disease in Japan.
    Mizuta I; Nishimura M; Mizuta E; Yamasaki S; Ohta M; Kuno S
    J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):350. PubMed ID: 12185186
    [No Abstract]   [Full Text] [Related]  

  • 89. Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.
    Singh S; Khayachi A; Milnerwood AJ; DeMarco ML
    J Parkinsons Dis; 2020; 10(2):613-621. PubMed ID: 32083592
    [TBL] [Abstract][Full Text] [Related]  

  • 90. alpha-Synuclein and Parkinson's disease.
    Burke RE
    Brain Res Bull; 1999; 50(5-6):465-6. PubMed ID: 10643486
    [No Abstract]   [Full Text] [Related]  

  • 91. [Genetics of Parkinson's disease].
    García de Yébenes J
    Neurologia; 2001 Jan; 16(1):1-6. PubMed ID: 11234656
    [No Abstract]   [Full Text] [Related]  

  • 92. Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology.
    Izco M; Blesa J; Schleef M; Schmeer M; Porcari R; Al-Shawi R; Ellmerich S; de Toro M; Gardiner C; Seow Y; Reinares-Sebastian A; Forcen R; Simons JP; Bellotti V; Cooper JM; Alvarez-Erviti L
    Mol Ther; 2019 Dec; 27(12):2111-2122. PubMed ID: 31501034
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Viral vectors as a tool to model and treat Parkinson's disease.
    Bensadoun JC; Aebischer P
    Wien Klin Wochenschr; 2006 Oct; 118(19-20):568-70. PubMed ID: 17136329
    [No Abstract]   [Full Text] [Related]  

  • 94. Protein aggregation in Huntington's and Parkinson's disease: implications for therapy.
    Wanker EE
    Mol Med Today; 2000 Oct; 6(10):387-91. PubMed ID: 11006527
    [TBL] [Abstract][Full Text] [Related]  

  • 95. No male predominance in alpha-synuclein Parkinson's disease but the affected female fetus might be less viable.
    Horstink MW; Bloem BR
    J Neurol Neurosurg Psychiatry; 2002 Feb; 72(2):276-7. PubMed ID: 11796789
    [No Abstract]   [Full Text] [Related]  

  • 96. [The neuroprotective B2 strengthens the aggregation of unfolded protein in Huntington chorea and Parkinson disease].
    Saur O; Stark H
    Pharm Unserer Zeit; 2006; 35(6):474-5. PubMed ID: 17137075
    [No Abstract]   [Full Text] [Related]  

  • 97. Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions.
    Leenders KL; Oertel WH
    Neural Plast; 2001; 8(1-2):99-110. PubMed ID: 11530892
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro.
    Necula M; Chirita CN; Kuret J
    J Biol Chem; 2003 Nov; 278(47):46674-80. PubMed ID: 14506232
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Ubiquitin and Parkinson's disease].
    Tashiro Y; Takahashi R
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1413-7. PubMed ID: 16922410
    [No Abstract]   [Full Text] [Related]  

  • 100. [Progress in diagnosis and therapy for Parkinson's disease].
    Mizuno Y
    Nihon Naika Gakkai Zasshi; 2002 Aug; 91(8):2344-8. PubMed ID: 12373846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.